Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von W illebrand factor levels-Reference-Cited by-同舟云学术

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von W illebrand factor levels

Published:2014-10-10 Issue:11 Volume:12 Page:1788-1800
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Shapiro A. D.¹,Ragni M. V.²,Kulkarni R.³,Oldenberg J.⁴,Srivastava A.⁵,Quon D. V.⁶,Pasi K. J.⁷,Hanabusa H.⁸,Pabinger I.⁹,Mahlangu J.¹⁰,Fogarty P.¹¹,Lillicrap D.¹²,Kulke S.¹³,Potts J.¹³,Neelakantan S.¹³,Nestorov I.¹³,Li S.¹³,Dumont J. A.¹³,Jiang H.¹³,Brennan A.¹³,Pierce G. F.¹³

Affiliation:

1. Department of Hematology Indiana Hemophilia and Thrombosis Center Indianapolis INUSA

2. University of Pittsburgh and the Hemophilia Center of Western Pennsylvania Pittsburgh PAUSA

3. Department of Pediatrics and Human Development Michigan State University East Lansing MI USA

4. Institut for Experimental Haematologie und Transfusionsmed Universitaetsklinikum Bonn Bonn Germany

5. Department of Hematology Christian Medical College Vellore India

6. Orthopedic Hemophilia Treatment Center Orthopedic Institute for Children Los Angeles CA USA

7. Barts and the London Comprehensive Care Centre London UK

8. Department of Hematology Ogikubo Hospital Suginami‐Ku Tokyo Japan

9. Universitätsklinik für Innere Medizin I Medizinische Universität Wien Wien Austria

10. Haemophilia Comprehensive Care Centre Faculty of Health Sciences University of the Witwatersrand and NHLS Johannesburg South Africa

11. Penn Comprehensive Hemostasis and Thrombosis Program Hospital of the University of Pennsylvania Philadelphia PA USA

12. Department of Pathology & Molecular Medicine Queen's University Kingston Ontario Canada

13. Biogen Idec Cambridge MA USA

Funder

Biogen Idec

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.12723

Reference50 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators;Soucie JM;Blood,2000

3. National Hemophilia Foundation.Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) 2007.http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed 18 July 2013.

4. Improvements in factor concentrates

5. Experience with estramustine phosphate;Nilsson T;Wis Med J,1976

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life;Journal of Clinical Medicine;2024-08-23

2. Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A;Drugs - Real World Outcomes;2024-08-10

3. Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis;Human Gene Therapy;2024-02-01

4. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults;Research and Practice in Thrombosis and Haemostasis;2023-08

5. No immunological changes after factor VIII product switch: An in depth analysis in haemophilia A patients;Haemophilia;2023-06-05